We found that response categories can be accurately predicted using pre-infusion product transcriptomes in three indications (CLL, ALL and LBCL) and two CD19-targeted products (Kymriah and Yescarta). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.